HC Wainwright Analysts Lift Earnings Estimates for Harrow

Harrow, Inc. (NASDAQ:HROW) – Investment analysts at HC Wainwright lifted their Q3 2025 earnings per share estimates for shares of Harrow in a research report issued on Wednesday, August 13th. HC Wainwright analyst Y. Chen now expects that the company will earn $0.10 per share for the quarter, up from their previous estimate of $0.02. HC Wainwright has a “Buy” rating and a $64.00 price target on the stock. The consensus estimate for Harrow’s current full-year earnings is ($0.53) per share. HC Wainwright also issued estimates for Harrow’s Q4 2025 earnings at $0.25 EPS and FY2026 earnings at $0.93 EPS.

Harrow (NASDAQ:HROW) last posted its earnings results on Monday, August 11th. The company reported $0.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.01 by $0.23. Harrow had a negative return on equity of 2.18% and a negative net margin of 4.49%. The firm had revenue of $63.74 million for the quarter, compared to analyst estimates of $64.23 million.

A number of other equities research analysts have also issued reports on HROW. Cantor Fitzgerald began coverage on Harrow in a research report on Friday, July 11th. They issued an “overweight” rating and a $76.00 price target on the stock. William Blair began coverage on Harrow in a research report on Tuesday, June 10th. They issued an “outperform” rating on the stock. Finally, BTIG Research reaffirmed a “buy” rating and issued a $63.00 price target (up previously from $62.00) on shares of Harrow in a research report on Thursday. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $64.67.

Harrow Price Performance

HROW opened at $38.82 on Friday. The company has a current ratio of 0.62, a quick ratio of 0.85 and a debt-to-equity ratio of 0.78. The firm has a market cap of $1.44 billion, a price-to-earnings ratio of -155.28 and a beta of 0.41. The stock’s 50-day moving average price is $33.18 and its 200 day moving average price is $28.91. Harrow has a 12-month low of $20.85 and a 12-month high of $59.23.

Institutional Investors Weigh In On Harrow

Hedge funds and other institutional investors have recently made changes to their positions in the business. GF Fund Management CO. LTD. acquired a new stake in shares of Harrow during the 4th quarter worth about $25,000. Quarry LP acquired a new position in Harrow during the first quarter worth approximately $32,000. Raymond James Financial Inc. acquired a new position in Harrow during the second quarter worth approximately $48,000. Tower Research Capital LLC TRC increased its position in Harrow by 769.5% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,652 shares of the company’s stock worth $55,000 after buying an additional 1,462 shares during the period. Finally, Aquatic Capital Management LLC acquired a new position in Harrow during the fourth quarter worth approximately $78,000. Institutional investors and hedge funds own 72.76% of the company’s stock.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.